This finding may have clinical ramifications, as humanized NGF blocking antibodies have been developed and are in clinical trials for the treatment of pain19; they may potentially be repurposed to inhibit the NGF-TrkA signaling axis in lung cancer. The gene discussed is NTRK1; the disease is lung cancer.